Key Highlights

  • Lifecore Biomedical (NASDAQ:LFCR) closed at USD 4.31 on September 8, 2026 and USD 6.44 on October 7, up about 49%, simple arithmetic. A published screen shows a one-month gain of 47.82%.
  • Webster Equity Partners agreed on September 28, 2026 to buy the company for USD 6.28 per share in cash plus one contingent value right, a premium of about 49.5% to the September 25 close.
  • The contingent value rights could pay up to USD 160 million in total, tied to 2028 and 2029 Revenue and a 2030 EBITDA target, and full payout would bring consideration to about USD 9.67 per share.
  • The deal needs a Lifecore Biomedical (NASDAQ:LFCR) stockholder vote and regulatory approvals, and it is expected to close by the end of the fourth quarter of 2026 after a 30-day go-shop period.

The Buyout Terms

Lifecore Biomedical, based in Chaska, Minnesota, agreed in a Merger agreement dated September 27, 2026 to be acquired by funds advised by Webster Equity Partners. Each common share receives USD 6.28 in cash at closing plus a non-tradable contingent value right. The release puts total value at up to USD 663.7 million assuming full milestone payments. Series A preferred holders receive cash equal to their conversion amount, about USD 50.2 million at June 30, 2026 or USD 6.53 per underlying common share, plus the rights. The board and its transaction committee approved the deal unanimously, and the common stock will be Delisted from Nasdaq at closing.

How the Rights Work

A contingent value right pays only if a milestone is met. Here the rights total up to USD 160 million: USD 30 million for a 2028 revenue milestone, USD 45 million for a 2029 revenue milestone and USD 85 million for a 2030 EBITDA milestone, with a 2029 catch-up for the first. Full payout would lift consideration to about USD 9.67 per share, but none is assured. That explains why the stock closed at USD 6.44 on October 7, above the USD 6.28 cash price: traders are pricing some value for the rights. Financing comes from MidCap Financial Trust, MSD Partners and Alcon Research Debt commitments plus Webster equity.

Risks and What to Watch

A 30-day go-shop lets Lifecore solicit rival bids, and the board may switch to a superior proposal under the agreement. Several analyst firms downgraded the stock after the announcement, including Barrington, William Blair and Craig-Hallum, which set a USD 6.28 target, as a buyout caps upside. Law firms have also announced investigations into the board's process. A proxy statement was filed September 28, 2026, and results are estimated for November 5, 2026. Closing depends on the stockholder vote and regulatory approvals, so timing could slip. No competing bid had been reported, and the stock's premium to the cash price shows investors expect some contingent value to be paid.

Where Things Stand

Lifecore Biomedical (NASDAQ:LFCR) jumped about 48% in a month because Webster Equity Partners agreed to buy it for USD 6.28 per share in cash plus rights worth up to USD 160 million in total. That makes this a deal-driven move, not an organic rally, and further upside depends on rival bids or the rights paying out. The stock trades slightly above the cash price. Watch the go-shop outcome, the stockholder vote and the year-end closing target. Lifecore Biomedical (NASDAQ:LFCR) holders should also note that the rights depend on future revenue.